Intestinal barrier dysfunction as a therapeutic target for cardiovascular disease

Area of Science:

• Cardiovascular Science
• Gastroenterology
• Immunology

Background:

• Gut microbiome alterations are linked to cardiovascular diseases (CVD) like hypertension, atherosclerosis, and heart failure.
• Increased intestinal permeability, a marker of gut dysfunction, is observed in CVD patients and models.
• This permeability can drive systemic inflammation and predict adverse cardiovascular outcomes.

Purpose of the Study:

• To review evidence linking intestinal barrier function to CVD pathogenesis.
• To explore the potential of targeting intestinal barrier function as a novel therapeutic strategy for CVD.

Main Methods:

• Review of key studies on intestinal permeability in various CVDs (hypertension, coronary artery disease, heart failure, myocardial infarction).
• Analysis of mechanisms underlying barrier dysfunction.
• Examination of emerging therapeutic strategies targeting the intestinal barrier.

Main Results:

• Increased intestinal permeability is associated with hypertension, atherosclerosis, and heart failure.
• Mechanisms of barrier breakdown and restoration are being elucidated.
• Therapies like short-chain fatty acids and probiotics show potential by improving barrier function.

Conclusions:

• While current evidence is largely associative, intestinal barrier function is a promising area for CVD research.
• Further studies are needed to confirm the role of barrier restoration and test targeted therapies.
• Targeting the intestinal barrier may lead to a new class of CVD therapeutics.